Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

A close-up of some pills

Healthcare Technologies and COVID-19: Speed is Not Always a Good Thing

With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.

Direct to long-term impacts of COVID-19

UK Response to COVID-19: Urgent Need for An Inclusive Transparent Decision Making Process

Following wide criticism of the way the government had been formulating and communicating its COVID-19 response, particularly on its scientific rationale, the UK government has initiated daily public briefings on the evolving crisis. Below we run through the UK government’s communications so far, and outline recommendations for the government to improve its communication ever further, by revamping its whole evidence-informed decision-making approach.